Browsing Tag
Morgan Stanley
103 posts
BT Group (LSE: BT.A) shares hit multi-year high as JP Morgan flags dividend doubling
BT Group's altnet bear case is fading. JP Morgan thinks the dividend doubles by 2030. The 21 May results will decide if the rerating sticks.
Tabcorp (ASX: TAH) collapse deepens as AUSTRAC compliance probe revives 2017 AML breach memories
Tabcorp paid A$45m for AML breaches in 2017. AUSTRAC just sent another letter. The market priced in the worst case before management could speak.
Catalyst Pharmaceuticals (CPRX) agrees $4.1bn buyout as Angelini Pharma plans to enter US rare disease market
Angelini Pharma will pay $4.1 billion for Catalyst Pharmaceuticals at $31.50 a share, but CPRX closed at $31.10. The premium sits in the strategy, not the price.
UltraTech Cement (NSE: ULTRACEMCO) tops Nifty after 200 MTPA milestone, Rs 240 dividend
UltraTech crossed 200 MTPA and paid a ₹240 special dividend, but petcoke at USD 153 is the test FY27 margins must survive before the rerating sticks.
Westpac shares run 3.1% as HY26 result and dividend chase fuel WBC bid
Westpac just delivered A$3.4bn profit and a 77c franked dividend. Brokers are still split between A$31 and A$40. The market has picked a side.
Vodafone (LSE: VOD) agrees £4.3bn buyout of CK Hutchison stake in VodafoneThree
Vodafone could have waited two more years to buy out CK Hutchison. It chose to pay £4.3 billion now. The synergy maths explains why.
Lattice Semiconductor bets $1.65bn on AMI to build secure data centre control platform
Lattice Semiconductor is paying $1.65 billion for AMI's firmware footprint inside every hyperscale server. The integration risk is the only thing standing between LSCC and a $1 billion run rate.
Arm Performix launches as Arm Holdings (NASDAQ: ARM) extends agentic AI play beyond silicon
Arm built the silicon. Now it wants to own the optimisation layer above it. Performix is free, agent-ready, and aimed squarely at the x86 migration question.
Why Goldman Sachs still sees $160bn in IPO proceeds despite fewer expected listings
Fewer IPOs, same $160bn target. Goldman Sachs’ reset shows why 2026 listings may depend on mega-deals. Read the full analysis.
Can The Real Brokerage Inc. (NASDAQ: REAX) unlock scale and margins through its $880m RE/MAX Holdings, Inc. (NYSE: RMAX) deal
Find out how The Real Brokerage Inc.’s REMAX acquisition could reshape real estate technology, franchising and agent productivity.